The use of thrombolytic agents has had a great impact on the management of acute myocardial infarction (AMI). It is clear that early administration of thrombolytics confers both functional and survival benefit. 1-Coronary thrombi are more susceptible to lysis when these agents are given early. 4 5 Streptokinase has been the main thrombolytic agent used in Sri Lanka for about a decade. Maximising the benefit of streptokinase and antiplatelet agents are important steps in improving the outcome of AMI. In this study we analyse the time delay encountered at various stages before the administration of streptokinase.
Subjects and methods
The study was conducted at the Institute of Cardiology of the National Hospital of Sri Lanka. We included 120 consecutive admissions for streptokinase therapy to the Coronary Care Unit (CCU) for a period of six months from May 1995. All patients were diagnosed to have AMI on clinical, electrocardiographic (ECG) and in many (98 patients) biochemical criteria.
All the patients were interviewed by the investigators regarding the time of onset of pain, prehospital medical advice, and time taken to arrive at the out-patient department. 
Results
Our study included 108 men (mean age 53 years) and 12 women (mean age 57 years). Anterior AMI was found in 61, inferior AMI in 50 and a combination in nine. The delay to initiation of thrombolysis was analysed in three different stages ( figure 1 and table) . The median prehospital delay was 130 minutes. Out of our 120 patients, 82 (68%) sought prehospital medical advice. The prehospital delay was significantly longer in this group compared with patients who came directly to the hospital (176 vs 85, Z = 5.2, p<0.001) (figure 2).
The median in-hospital delay was 70 minutes. The length of the in-hospital delay was partly dependent on the mode of admission to the CCU. The 56 patients (47%) who were initially sent to general medical wards had a significantly longer delay than those sent directly to the CCU (129 vs 61, Z = 5.8, p<0.001) (figure 3).
Discussion
The benefits of early thrombolytic therapy are well established. A meta-analysis of the time to thrombolytic therapy showed the absolute reduction in mortality per hour of delay to be 1.6 (SD 0.6) per 1000 patients,6 and modern guidelines for the management of AMI emphasise the need for early treatment. Ischaemic heart disease is a growing problem in developing countries. 22 Hence, economically feasible measures to salvage the myocardium should be explored to the maximum.
